In the phase II KEYNOTE-002 study, patients with ipilimumab-refractory melanoma were randomized to pembrolizumab or investigator choice chemotherapy, and the patients with BRAF V600-mutated were treated with BRAF inhibitor. This evidence concerns the gene BRAF and melanoma.